# EDGAR Filing Document

**Accession Number:** 0001531978
**File Stem:** 0000950170-23-000549
**Filing Date:** 2023-1
**Character Count:** 10351
**Document Hash:** fb56da5fe7fbe00e9ad65bbb117f769e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000549.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0000950170-23-000549

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230110

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Paragon 28, Inc.
- **CENTRAL INDEX KEY:** 0001531978
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 273170186
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40902
- **FILM NUMBER:** 23519607

**BUSINESS ADDRESS:**
- **STREET 1:** 8310 SOUTH VALLEY HIGHWAY
- **STREET 2:** SUITE 3115
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** 888-728-1888

**MAIL ADDRESS:**
- **STREET 1:** 8310 SOUTH VALLEY HIGHWAY
- **STREET 2:** SUITE 3115
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 10, 2023<br>

------

Paragon 28, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40902 | 27-3170186 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 14445 Grasslands Drive |  |  |
| Englewood**,** Colorado |  | 80112 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (720) 912-1332<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.01 par value<br> FNA | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On January 10, 2023, Paragon 28, Inc. (the "Company") issued a press release announcing preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. A copy of the Company's press release, titled "Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit Number** | &nbsp;&nbsp;**Description of Exhibit** |
| &nbsp;&nbsp;99.1 | &nbsp;&nbsp;[<u>Press Release, dated January 10, 2023, titled "Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022"</u>](fna-ex99_1.htm) |
| &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PARAGON 28, INC.** | **PARAGON 28, INC.** |
| Date: January 10, 2023 | By: | /s/ Jonathan Friedman |
|  |  | Jonathan Friedman |
|  |  | General Counsel |

---

------

## Exhibit 99.1

![img260534060_0.jpg](img260534060_0.jpg)

**Exhibit 99.1**

**Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022**

ENGLEWOOD, Colo. – January 10, 2023 (BUSINESS WIRE) – Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022.

Preliminary unaudited net revenue for the fourth quarter of 2022 is expected to be in a range of $51.2 to $51.5 million, representing reported growth of approximately 20% compared to the fourth quarter of 2021. These results reflect foreign currency headwinds which are expected to reduce preliminary unaudited fourth quarter 2022 net revenue growth and net revenue by 1.6 percentage points and $0.7 million, respectively, as compared to the fourth quarter of 2021.

Preliminary unaudited net revenue for the full-year of 2022 is expected to be in a range of $181.0 to $181.3 million, reflecting growth of approximately 23.0% compared to the full-year of 2021. These results reflect foreign currency headwinds which are expected to reduce preliminary unaudited full-year 2022 net revenue growth and net revenue by 1.4 percentage points and $2.1 million, respectively, as compared to the full-year of 2021.

The Company will provide 2023 financial guidance when it releases its fourth quarter 2022 financial results later this quarter.

"Paragon 28 has had stand-out performance since our IPO in October 2021, and we are more excited than ever about the strength of our business as we begin 2023." said Albert DaCosta, Chairman and CEO of Paragon 28.

**About Paragon 28, Inc.**

Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

------

![img260534060_0.jpg](img260534060_0.jpg)

**Forward Looking Statements**

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28's potential to shape a better future for foot and ankle patients and its estimated ranges of net revenue for the fourth quarter and full-year of 2022. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled "Risk Factors" in Paragon 28's filings with the Securities and Exchange Commission (the "SEC"), including Paragon 28's annual report on Form 10-K filed with the SEC on March 8, 2022. Paragon 28 does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing Paragon 28's views as of any date subsequent to the date of this press release. Paragon 28's preliminary unaudited estimated revenue for the quarter ended December 31, 2022 and the year ended December 31, 2022 are not necessarily indicative of our operating results for any future periods.

**Investor Contact:**

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (741) 336-0435

mbrinckman@paragon28.com

------